Roxithromycin: Advanced Macrolide Antibiotic for Effective Bacterial Control
| Product dosage: 150mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.85 | $50.74 (0%) | 🛒 Add to cart |
| 90 | $0.77 | $76.11 $69.66 (8%) | 🛒 Add to cart |
| 120 | $0.73 | $101.48 $87.72 (14%) | 🛒 Add to cart |
| 180 | $0.70 | $152.22 $125.56 (18%) | 🛒 Add to cart |
| 270 | $0.67 | $228.33 $181.46 (21%) | 🛒 Add to cart |
| 360 | $0.66
Best per pill | $304.44 $239.08 (21%) | 🛒 Add to cart |
Synonyms
| |||
Roxithromycin is a semi-synthetic macrolide antibiotic derived from erythromycin, designed to offer enhanced pharmacokinetic properties and a broad spectrum of antibacterial activity. It functions by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit, making it effective against numerous Gram-positive and some Gram-negative pathogens, as well as atypical bacteria. Its improved acid stability and tissue penetration compared to earlier macrolides allow for convenient once- or twice-daily dosing, supporting patient adherence and treatment efficacy in both community and clinical settings.
Features
- Semi-synthetic 14-membered ring macrolide antibiotic
- Broad-spectrum activity against Gram-positive cocci, some Gram-negative bacteria, and intracellular pathogens
- High oral bioavailability and extended half-life (~12 hours)
- Acid-stable formulation, allowing administration without regard to meals
- Effective tissue penetration, including respiratory tract and skin
- Available in 150 mg and 300 mg film-coated tablets
Benefits
- Effectively treats respiratory tract infections, including community-acquired pneumonia and acute bronchitis
- Provides reliable coverage for skin and soft tissue infections caused by susceptible organisms
- Convenient dosing regimen improves compliance and reduces missed doses
- Generally well-tolerated with a favorable safety profile in most patient populations
- Suitable for patients with penicillin allergies where macrolides are indicated
- Demonstrates anti-inflammatory properties in addition to antibacterial effects
Common use
Roxithromycin is indicated for the treatment of mild to moderate bacterial infections caused by susceptible microorganisms. Common clinical applications include upper and lower respiratory tract infections such as pharyngitis, tonsillitis, sinusitis, acute bronchitis, and community-acquired pneumonia. It is also prescribed for skin and soft tissue infections including erysipelas, impetigo, and secondary infected dermatoses. Additionally, roxithromycin may be used for genitourinary infections caused by Chlamydia trachomatis and other susceptible organisms. Off-label uses may include prophylaxis against bacterial endocarditis in high-risk patients undergoing dental procedures who are allergic to penicillin, though this application requires careful risk-benefit assessment.
Dosage and direction
The standard adult dosage is 300 mg daily, administered either as a single dose or in two divided doses of 150 mg every 12 hours. For more severe infections, the dose may be increased to 300 mg twice daily. The usual duration of treatment is 5 to 10 days, depending on the type and severity of infection. For streptococcal infections, a minimum 10-day course is recommended to prevent rheumatic fever. Pediatric dosing is typically 5-8 mg/kg/day in two divided doses, not to exceed 300 mg daily. Tablets should be swallowed whole with a glass of water and may be taken with or without food, though administration with food may help minimize gastrointestinal discomfort. Dosage adjustment is necessary in patients with severe hepatic impairment, typically reducing the dose by 50%.
Precautions
Roxithromycin should be used with caution in patients with hepatic impairment, as the drug is primarily metabolized by the liver. Regular liver function tests are recommended during prolonged therapy. Patients with pre-existing cardiac conditions, particularly those with prolonged QT interval, should be monitored closely due to the potential for macrolides to prolong cardiac repudiation. Caution is advised when prescribing to patients with myasthenia gravis, as macrolides may exacerbate muscle weakness. The possibility of developing Clostridium difficile-associated diarrhea should be considered in patients presenting with diarrhea during or after treatment. Use during pregnancy should be limited to cases where the potential benefit justifies the potential risk to the fetus, as safety data in pregnancy is limited. Nursing mothers should exercise caution, as roxithromycin is excreted in breast milk.
Contraindications
Roxithromycin is contraindicated in patients with known hypersensitivity to macrolide antibiotics or any component of the formulation. It should not be used concurrently with ergot derivatives, cisapride, pimozide, or terfenadine due to the risk of serious cardiac arrhythmias. Contraindication extends to patients with history of hepatitis or jaundice associated with previous macrolide use. The drug is contraindicated in patients with severe hepatic impairment without appropriate dose adjustment and monitoring. Concomitant use with colchicine is contraindicated in patients with renal or hepatic impairment.
Possible side effect
The most commonly reported adverse reactions involve the gastrointestinal system, including nausea (3-4%), abdominal pain (2%), diarrhea (2-3%), and vomiting (1%). Less frequent side effects include headache (1-2%), dizziness, and skin rash. Hepatic effects may include transient elevations in liver enzymes and, rarely, hepatitis or cholestatic jaundice. Cardiac effects may include QT prolongation and, in rare cases, ventricular arrhythmias. Other potential adverse effects include oral candidiasis, vaginitis, taste disturbances, and rarely, hearing loss with high doses or renal impairment. Pseudomembranous colitis has been reported with most antibacterial agents, including roxithromycin.
Drug interaction
Roxithromycin may increase plasma concentrations of drugs metabolized by CYP3A4, including calcium channel blockers, statins, benzodiazepines, and some antidepressants. Concurrent use with warfarin may enhance anticoagulant effect, requiring close monitoring of INR. Concomitant administration with ergot alkaloids may cause ergotism. The drug may increase concentrations of digoxin, theophylline, and cyclosporine, necessitating dosage adjustments and monitoring. Antacids and H2-receptor antagonists do not significantly affect roxithromycin absorption. Concomitant use with other QT-prolonging agents may increase the risk of cardiac arrhythmias. Rifampicin significantly decreases roxithromycin concentrations through CYP450 induction.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Doubling the dose to make up for a missed dose is not recommended. Patients should be advised to maintain as consistent a dosing schedule as possible to ensure maintained therapeutic blood levels. If multiple doses are missed, patients should contact their healthcare provider for guidance on resuming therapy.
Overdose
Symptoms of overdose may include severe nausea, vomiting, diarrhea, and abdominal pain. In severe cases, hearing loss, pancreatitis, or QT prolongation may occur. Management is primarily supportive and symptomatic. Gastric lavage may be considered if performed soon after ingestion. Activated charcoal may be administered to reduce absorption. Cardiac monitoring is recommended in cases of significant overdose, particularly in patients with pre-existing cardiac conditions. There is no specific antidote for roxithromycin overdose. Hemodialysis is not effective for removal of the drug due to high protein binding and extensive tissue distribution.
Storage
Store at room temperature between 15-30°C (59-86°F) in the original container, protected from light and moisture. Keep the medication in a secure location out of reach of children and pets. Do not store in bathrooms or other areas with high humidity. Do not use beyond the expiration date printed on the packaging. Properly discard any unused medication after completion of therapy or upon expiration. Do not flush medications down the toilet or pour them into a drain unless instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read in this product information. The manufacturer and distributors are not liable for any damages resulting from the use or misuse of this information.
Reviews
Clinical studies demonstrate roxithromycin’s efficacy in respiratory tract infections with clinical success rates of 85-92% in comparative trials. Meta-analyses show comparable efficacy to other macrolides with potentially improved gastrointestinal tolerability. Post-marketing surveillance data indicates favorable patient acceptance due to the convenient dosing schedule. Specialist reviews note its particular value in community-acquired pneumonia and skin infections where atypical coverage is needed. Some studies suggest potential anti-inflammatory benefits beyond antibacterial activity in chronic respiratory conditions. Long-term safety data from European and Asian markets support its well-tolerated profile when used appropriately.